Following on from information provided to NICE by the company in July 2017 the appraisal of Multiple myeloma (treated) – pembrolizumab was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1139
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2017 the appraisal of Multiple myeloma (treated) – pembrolizumab was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 August 2017 | Suspended. The company have recently advised that they will not be pursuing a licensing application for pembrolizumab from the European Medicines Authority for this indication at this time. |
| 03 August 2017 | Note added to the project documents |
| 29 March 2017 - 28 April 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 March 2017 | Referral |
| 05 December 2016 | In progress. Topic Referred |
For further information on our processes and methods, please see our CHTE processes and methods manual